Future of drugs-Diabetes_Luseogliflozin
Drug
Name
|
Luseogliflozin
|
Structure
|
|
Drug Code
|
TS-071
|
Synonym
|
(2S,3R,4R,5S,6R)-2-[5-(4-Ethoxybenzyl)-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)tetrahydro-2H-thiopyran-3,4,5-triol
|
Molecular Formula
|
C23H30O6S
|
Innovator
|
Taisho Toyama Pharmaceutical
Novartis for marketing
|
Condition
|
Type-2 diabetes mellitus
|
Mechanism of Action
|
Sodium-glucose transporter
2 inhibitor
|
Clinical Phase
|
I
|
Approval
|
Approved in Japan in March
2014.
|
Comments
Post a Comment